| 99.64 -1.36 (-1.35%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 124.82  |
1-year : | 130.65 |
| Resists | First : | 106.87 |
Second : | 111.86 |
| Pivot price | 104.1 |
|||
| Supports | First : | 98.8 |
Second : | 82.2 |
| MAs | MA(5) : | 102.26 |
MA(20) : | 104.31 |
| MA(100) : | 93.26  |
MA(250) : | 73.73 |
|
| MACD | MACD : | -0.6 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 12.9 |
D(3) : | 23.5 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 111.86 | Low : | 47.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LNTH ] has closed above bottom band by 6.2%. Bollinger Bands are 8.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 101.16 - 101.65 | 101.65 - 102.13 |
| Low: | 97.36 - 97.98 | 97.98 - 98.59 |
| Close: | 98.49 - 99.47 | 99.47 - 100.44 |
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Fri, 31 Jul 2026
Lantheus Holdings (LNTH): Vanguard Portfolio Management reports 5.06% ownership stake - Stock Titan
Fri, 31 Jul 2026
ETFs Investing in Lantheus Holdings Inc Stocks - TradingView
Thu, 30 Jul 2026
LNTH|Lantheus Holdings Inc|Price:100.850|Chg%:+0.850 - TradingKey
Tue, 28 Jul 2026
Lantheus Holdings, Inc. Stock 12‑Month Price Target Raised to $113.82, Implies 5% Upside - TradingView
Mon, 27 Jul 2026
Market Chatter: Curium in Talks to Acquire Lantheus For $7 Billion - Moomoo
Mon, 27 Jul 2026
Curium in talks to buy Lantheus Holdings for about $7B - Bloomberg (LNTH:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 65 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 116.4 (%) |
| Shares Short | 6,400 (K) |
| Shares Short P.Month | 6,050 (K) |
| EPS | 4.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.62 |
| Profit Margin | 18 % |
| Operating Margin | 21.6 % |
| Return on Assets (ttm) | 8.1 % |
| Return on Equity (ttm) | 23.4 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 14.36 |
| Sales Per Share | 23.8 |
| EBITDA (p.s.) | 5.62 |
| Qtrly Earnings Growth | 76.5 % |
| Operating Cash Flow | 408 (M) |
| Levered Free Cash Flow | 422 (M) |
| PE Ratio | 23.78 |
| PEG Ratio | 0 |
| Price to Book value | 5.34 |
| Price to Sales | 4.18 |
| Price to Cash Flow | 15.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|